Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355138 | 0.80 | MEN1 (0.59) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL16216174 | 0.79 | HTR3E (0.49) | RAB9ANPC1ALOX12MAPT | |
| Hydrochloric Acid SCHEMBL16372135 | 0.78 | ALOX12 (0.50) | MEN1KMT2ACYP2C19ALDH1A1HPGD | |
| Iodide SCHEMBL11389787 | 0.78 | MEN1 (0.52) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL27467998 | 0.78 | GAA (0.49) | CYP2C9ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1709315 | 0.77 | HPGD (0.70) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL20825142 | 0.77 | MEN1 (0.55) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL5064965 | 0.76 | MEN1 (0.59) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL4018773 | 0.76 | CYP2C9 (0.66) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL8895096 | 0.76 | MEN1 (0.59) | MEN1KMT2ACYP2C19CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044169-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | UNIV LELAND STANFORD JUNIOR (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044169-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | HAVCR2, MAVS, EIF2AK2 | MEN1 4779/4885KMT2A 3751/4885CYP2C19 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.